Exploring the Future of Psychedelic Therapy in Clinical Practice

Integrative Practitioner Podcast

Emily Whinkin, ND, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss how the Federal Drug Administration’s (FDA) rejection of MDMA-assisted therapy for PTSD impacts the future of psychedelic therapy in the United States.

Find us at integrativepractitioner.com or e-mail us at [e-mail].

Theme music: "Upbeat Party" by Scott Holmes via freemusicarchive.org and "Carefree" by Kevin Mcleod via incompetech.com.

About the Expert

Emily Whinkin, ND (she/they), is an integrative mental health practitioner, researcher, and psychonaut currently practicing at the Advanced Integrative Medical Science Institute in Seattle. She holds Washington and Oregon licenses in naturopathic medicine and graduated with a master of science degree in integrative mental health from the National University of Natural Medicine in Portland, OR. Clinically, Whinkin works to provide person-centered, relationally informed care at the confluence of entheogenic spiritual medicine, mental health, and reproductive/generative health. As an undergraduate, she studied both biology and religious studies, formally launching her work to explore and affirm the interdependence of mind, body, and spirit with a focus on cycles, transitions, and environment. Community connection, belonging, and collective transformation are central to Whinkin's vision of being well in the world. She works to reflect this framework in caring for each patient’s foundational vitality, resilience, and health contexts as 'root cause' approaches to healing. She is certified in perinatal mental health (PMH-C) by Postpartum Support International and Holistic Pelvic Care™ with Tami Kent, and she often weaves mindful somatic therapy and botanical medicine within psycho-spiritual work with all genders across the lifespan.